X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/cantex-pharmaceuticals-announces-four-abstracts-to-be-presented-featuring-azeliragon-at-2024-asco-annual-meeting-302155456.html
https://www.prnewswire.com/news-releases/cantex-pharmaceuticals-receives-fda-orphan-drug-designation-for-azeliragon-for-the-treatment-of-pancreatic-cancer-302150254.html
https://www.prnewswire.com/news-releases/cantex-pharmaceuticals-to-present-at-5th-annual-glioblastoma-drug-development-summit-302092381.html
https://www.prnewswire.com/news-releases/cantex-and-michigan-medicine-announce-initiation-of-a-randomized-double-blind-placebo-controlled-multicenter-phase-3-pivotal-clinical-trial-to-evaluate-the-safety-and-efficacy-of-azeliragon-in-the-treatment-of-patients-hospita-301939862.html
https://www.prnewswire.com/news-releases/cantex-and-allegheny-health-network-announce-initiation-of-a-phase-12-study-of-azeliragon-in-patients-refractory-to-first-line-treatment-of-metastatic-pancreatic-cancer-301936563.html
https://www.prnewswire.com/news-releases/cantex-pharmaceuticals-and-lenox-hill-hospital-announce-initiation-of-a-phase-2-study-of-rage-inhibitor-azeliragon-as-a-front-line-treatment-for-unmethylated-glioblastoma-301930043.html
https://www.prnewswire.com/news-releases/cantex-pharmaceuticals-announces-initiation-of-an-investigator-initiated-phase-2-clinical-trial-investigating-azeliragon-combined-with-stereotactic-radiosurgery-for-the-treatment-of-brain-metastases-301911475.html
https://www.prnewswire.com/news-releases/cantex-pharmaceuticals-announces-article-published-in-npj-breast-cancer-highlighting-potential-role-of-rage-inhibition-to-prevent-metastasis-in-triple-negative-breast-cancer-301897258.html
https://www.prnewswire.com/news-releases/cantex-pharmaceuticals-to-present-at-the-medinvest-oncology-investor-conference-in-boston-301851424.html
https://www.prnewswire.com/news-releases/cantex-pharmaceuticals-obtains-exclusive-worldwide-rights-to-intellectual-property-from-georgetown-university-for-azeliragon-as-a-potential-treatment-of-cancer-related-cognitive-decline-301840270.html
Market Place
Share 
